New combo drug CagriSema shows promise for diabetes control

NCT ID NCT06403761

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 trial tested CagriSema, a new combination of two medicines (cagrilintide and semaglutide), in 158 adults with type 2 diabetes. Participants received either CagriSema, one of the individual drugs, or a placebo, alongside their usual metformin. The study measured how well the body responds to insulin, aiming to see if CagriSema improves insulin sensitivity and pancreatic function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CagriSema (combination of cagrilintide and semaglutide)
What this could lead to: If successful, this could lead to a new treatment option that improves how the body uses insulin in people with type 2 diabetes.
What could go wrong: This is an early Phase 1 study, so results are preliminary. The drug may not show significant benefit over existing treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Profil Institut für Stoffwechselforschung GmbH

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.